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Over the past two decades there has been dramatic progress in the development and evaluation of therapies
for lysosomal storage disorders, several of which are now in routine clinical use or in clinical trials. The
greatest current challenge is in developing effective therapies for treating the CNS manifestations of these
complex disorders. In this article, we will review the current therapies/approaches being considered for
treating lysosomal storage diseases and give a perspective on the scientiﬁc, medical, social and ethical issues
they raise.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Lysosomal storage diseases (LSDs) are a diverse group of
hereditary metabolic disorders that are typically inherited in an
autosomal recessive manner. Approximately forty-ﬁve diseases have
been described to date [1]. They are caused by defects in multiple
aspects of lysosomal function, most commonly mutations in genes
that encode catabolic enzymes involved in the degradation of
macromolecules [2]. The substrate for the defective enzyme builds
up over time (storage), leading to cell dysfunction and progressive
clinical manifestations [3]. Other forms of lysosomal dysfunction that
can also lead to lysosomal storage include defects in post-translational
processing of lysosomal enzymes, errors in enzyme trafﬁcking/
targeting and defective function of non-enzymatic lysosomal trans-
membrane and soluble proteins [4].
There are two complementary yet distinct classiﬁcation schemes
for these diseases. The ﬁrst classiﬁes on the basis of the biochemical
nature of the storage material(s) [4]. This is very useful but runs into
problems when multiple substrates are stored in a single disorder,
which is not an uncommon scenario [5]. The second scheme classiﬁes
these disorders based on the underlying mechanism causing disease
[4]. For example, all diseases resulting from enzyme deﬁciencies
would be in one category, irrespective of the type of macromolecule
that is stored. This is a conceptually useful scheme when trying to
understand basic mechanisms of pathogenesis and is crucial for the
rational design of new therapies.. Platt),
ll rights reserved.In this article, we will brieﬂy review the cell biological and clinical
features of these diseases and discuss the progress towards the
development of effective treatments. We will also discuss the implica-
tions of diseasemodifying therapies on quality of life for patients, health
care provision and funding and the potential role of screening.
2. Clinical aspects of LSDs
The majority of LSDs (over two thirds) are caused by mutations in
lysosomal hydrolases, which are involved in the degradation of
cellular macromolecules [2]. The biochemical nature of storage
products in LSDs is therefore diverse and includes mucopolysacchar-
ides, glycogen, glycoproteins and various classes of lipids. With the
exception of Danon, Fabry and Hunter diseases, which are X-linked
disorders, the LSDs are all inherited as autosomal recessive traits [6].
The LSDs are clinically highly diverse and can affect most organs,
either in isolation or as part of a multisystem disorder. Although
lysosomal enzymes are housekeeping genes and are expressed in
most cells, the substrates upon which they act have a much less
uniform tissue distribution, and this will determine which tissues are
affected in any individual disease. Hence ganglioside expression is,
particularly high in the nervous system and the gangliosidoses are
neurodegenerative diseases. Keratan and dermatan sulphate are
expressed at high levels in skeletal tissue and the mucopolysacchar-
idoses, which involve defects of their degradation pathways' are
characterised by dysostosis multiplex (severe abnormalities in
development of skeletal cartilage and bone).
There is also considerable variation within each disorder, ranging
from severe, infantile-onset forms to attenuated adult-onset disease,
sometimes with distinct clinical features. It would seem logical to
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metabolic pathway involved [7].
Hence, if we take Gaucher disease as an example [8], complete
enzyme deﬁciency is not compatible with extra-uterine life and
results in hydrops fetalis and the collodion baby phenotype. Where
there is minimal enzyme activity, storage rapidly occurs in a variety of
tissues including neurones, resulting in the infantile neuronopathic
phenotype (type 2 disease), which is rapidly fatal. Even just a few
percent residual activity can be enough to prevent storage in most
tissues and avoid neurodegeneration. However, the macrophages of
the reticuloendothelial system, which have to break down enormous
amounts of glycosphingolipid due to their role in phagocytosis of
effete blood cells in the spleen, liver and bone marrow, store high
levels of glucosylceramide and the attenuated, late-onset form of
Gaucher disease (type 1 disease) is characterised by hepatospleno-
megaly and bone involvement. In between these two phenotypes are
some individuals who have severe systemic and skeletal disease along
with brainstem involvement (traditionally called type 3 disease),
suggesting that there may be some neuronal subtypes which are
particularly sensitive to glucocerebrosidase deﬁciency [9].
This hypothesis is at least partially supported by genotype–
phenotype correlation, and there are some ‘severe’ genotypes
which, in homozygotes or compound heterozygotes, are inevitably
associated with neuronopathic disease [10]. But genotype/phenotype
relationships are much less well deﬁned for the majority of mutations
which give rise to attenuated disease, and it is common for sibling
pairs and even twins to demonstrate highly divergent clinical features
as regards age of onset and degree of skeletal involvement [11].
Similar inconsistencies exist for other LSDs and the difﬁculties in
predicting phenotype from genotype have major implications in
diseases where newborn screening is currently being considered. The
epigenetic and environmental modiﬁers that lead to this poor
correlation between phenotype and genotype still remain ill-deﬁned,
but once elucidated could offer novel approaches to the development
of disease modifying therapies.
3. Cell biology of LSDs
The storage of any lysosomal substrate triggers an expansion in the
lysosomal compartment, both in terms of size and number of
lysosomes. However, the expansion of the lysosomal compartment
alone does not lead to cell death via mechanical damage; more subtle
mechanisms cause cell dysfunction and ultimately cell loss. For
example, over the past few years several hypotheses have been
proposed to explainwhy lipid storage in the lipidoses leads to disease.
One theory suggests that the storage of glycosphingolipids (which can
be a primary or secondary feature of abnormal metabolism) causes an
expansion in raft membranes in the endocytic system, leading to the
inappropriate retention of cell surface receptors normally involved in
plasma membrane raft signalling events [12]. A second theory
proposes that stored glycosphingolipids (GSLs) do not remain
conﬁned to the lysosome but also build up in other cellular
membranes where they may negatively impact normal homeostatic
processes [13]. This concept has been proven biochemically in type 1
Gaucher diseasewhere analysis of fractionated cells revealed the build
up of GlcCer in many different organelle membranes [14]. This is also
consistent with the observation from electron microscopy studies that
the electron density of membranes in cells storing lipids is not
conﬁned to the late endosomal/lysosomal system (LE/Lys).
The presence of storage lipids in membranes throughout the cell
offers many more potential mechanisms through which cell dysfunc-
tion can occur, beyond the conﬁnes of the lysosome itself. For
example, a common ﬁnding in the glycosphingolipidoses is altered
calcium homeostasis, speciﬁcally elevated cytosolic calcium due to
defective ER calcium regulation [13]. This is proposed to result from
the storage lipid building up in ER membrane and modulating thefunction of ER calcium channels [13]. This renders cells such as
neurons vulnerable to excitoxicity, which may in part explain cell
dysfunction/cell loss in the brain in some of these disorders [15].
An almost universal defect in cells storing sphingolipids is the
altered trafﬁcking of the sphingolipid probe BODIPY-LacCer [16,17].
Similar ﬁndings have been reported with cholera toxin staining of
endogenous cellular GM1 [17]. The functional consequences of this
trafﬁcking defect are not fully elucidated but clearly trafﬁcking is
affected by the storage of multiple different lipids, irrespective of their
precise biochemical composition [16]. At a practical level, this serves
as a useful assay for monitoring response to therapy [16,18].
4. Secondary consequences of storage
As described above, the storage of macromolecules in the LE/Lys
can trigger cellular dysfunction and impact on physiological systems.
In order to elucidate the secondary consequences of storage, authentic
animal models are required and the LSD ﬁeld is fortunate in having
spontaneous (various species) and/or engineered mouse models for
most disorders [19]. These animal models have proved invaluable for
studying pathophysiology and also for testing new approaches to
therapy.
In animal models with pathology in the brain, the most prominent
and universal secondary consequence of storage is inﬂammation in
the CNS [20]. Most data suggest that this is due to activation of the
innate immune system, withmicroglial cells andmacrophages playing
a prominent role [21,22]. However, additional involvement of
autoimmune pathophysiology has also been suggested in a small
number of studies [23].
Targeting inﬂammation has been proven to be of therapeutic
beneﬁt; preventing macrophage recruitment to the brain in a mouse
model of Sandhoff disease extended life span of these mice [24], as did
treatment with non-steroidal anti-inﬂammatory drugs (NSAIDs) [25].
As yet there have been no clinical studies evaluating NSAIDs in
patients with LSDs.
5. Therapy
5.1. Metabolic cross-correction
Most lysosomal hydrolases are targeted to lysosomes viamannose-
6-phosphate (M6P) receptors [26] (one notable exception is gluco-
cerebrosidase, the enzyme deﬁcient in Gaucher disease which has
been proven to be transported to lysosomes by LIMP2 [27]). Lysosomal
enzymes are glycoproteins that are synthesised in the ER and are
transported via the Golgi in the same way as secreted proteins [28].
The addition of M6P residues results in transport to the lysosome, but
a percentage of molecules (that varies depending on the speciﬁc
enzyme in question) fail to enter this pathway and are instead
secreted from the cell. [28]. This secreted enzyme is available for re-
capture by the same cell, or neighbouring cells, via cell surface M6P
receptors that target the internalised enzyme into the endocytic
pathway and ultimately to the lysosome [28].
This facet of lysosomal enzyme cell biology has profound
therapeutic implications as diseased cells can take up exogenous
enzyme which is then delivered to the lysosome where it can degrade
stored substrate and restore homeostasis. This exogenous enzyme
could be made outside the body and infused into the blood, or
approaches such as gene therapy and stem cell transplantation could
be used. With these latter approaches, as long as a few cells are of
donor origin or transduced with the corrective gene, they can supply
surrounding tissues with corrective enzyme via the secretion–
recapture mechanism [28].
Therefore, the therapeutic hurdle that needs to be crossed in LSDs,
which are due to deﬁciencies of lysosomal hydrolases is considerably
lower than in other monogenic diseases, as not every cell needs to be
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enzyme activity can have a profound impact on clinical presentation,
LSDs are very attractive targets for developing such therapies as there
is a realistic prospect of success, even with only modest levels of
correction.
5.2. Application of metabolic cross-correction
5.2.1. Stem cell therapy. The ability to achieve cross-correction by
secretion-reuptake of lysosomal hydrolases make LSDs a very attrac-
tive target for stem cell therapy [29] and allogeneic bone marrow
transplantation was the ﬁrst speciﬁc therapeutic approach to be used
in LSDs. The introduction of this approach in the 1980s was hypothesis
driven rather than being based on experimental evidence and has to a
large extent been done on a case by case basis [30]. More than 20 years
later it is still difﬁcult to draw any evidence-based conclusions about
the use of this potentially powerful treatment in LSDs.
The vast majority of clinical experience is in treating patients with
mucopolysaccharidoses, particularly MPS I. Because of the risks
associated with the procedure, allogeneic BMT has generally been
used in the more severe, Hurler form of MPS I and the vast majority of
children have been transplanted before the age of three. BMT is
effective in reducing visceromegaly and cardiac function and airway
obstruction improve [31]. Although there can be improvements in
mobility due to reductions in soft tissue storage, effects on the
skeleton are less obvious and patients do not grow normally after
transplantation [32]. Perhaps surprisingly, as one would not expect
enzyme secreted from haematopoietic cells to cross the blood brain
barrier, BMT can also halt neurodegeneration in some patients, if
transplanted early enough, and a decrease in white matter lesions on
brain MRI has been reported [33].
This efﬁcacy against CNS disease is due to the fact that the
microglia in the brain are derived from bonemarrow precursors. After
allogeneic BMT the brain gradually becomes repopulated with
microglia of donor origin, and these then act as a source of secreted
enzyme to correct other cell types within the CNS [29]. This
observation underlies the use of allogeneic BMT in leucodystrophies.
In Krabbe disease (globoid cell leucodystrophy), BMT can prevent
disease if given to infants before symptoms develop [34]. In juvenile
onset forms, haematopoietic stem cell transplantation (HSCT) has
been shown to slow or abort disease progression in some cases,
although there is a delay of several months after transplantation
before any effects are seen, presumably representing the time it takes
for donor-derived microglia to repopulate the recipient's CNS. In the
past, the high morbidity and mortality associated with standard
myeloablative protocols utilized in HCST have limited its use, but
newer, reduced intensity conditioning regimes may allow allogeneic
BMT to be more widely used in the older patients, with more
attenuated disease, for whom it is most likely to be effective in
arresting disease progression [35].
Haematopoietic stem cell transplants have been tried in a number
of other LSDs (MPS I, metachromatic leucodystrophy, neuronopathic
Gaucher disease) [36]. On the whole these have only been reported
anecdotally, or as small case series [37,38]. It is difﬁcult to draw ﬁrm
conclusions about the use of HSCT in these conditions due to the
piecemeal manner in which procedures have been done: different
centres have performed small numbers of procedures on patients of
varying age and clinical status using different protocols and
preconditioning regimes. With recent developments making allo-
geneic BMT safer and more widely available, it may be worth re-
evaluating its use in a range of LSDs where no other speciﬁc therapy is
available, but, if this treatment modality is to be developed further, a
more systematic approach will have to be taken.
5.2.2. Neural stem cell therapy. The major limitation of BMT is that
only a very small number of cells of bonemarrow originmigrate to thebrain and differentiate into CNS resident macrophages (microglia).
This is because microglia are long lived and turn over very slowly [39].
The CNS therefore remains largely uncorrected following BMT.
One potential way to solve this problem is to transplant wild type
neural stem cells into the CNS, with the prospect that these
transplanted cells will migrate, integrate into neural circuitry and
most importantly will secrete enzyme that can cross-correct the local
microenvironment in the vicinity of the transplanted cells [40]. As
well as acting as a source of the deﬁcient enzyme, this cell-based
therapy could potentially be of clinical beneﬁt through other
mechanisms of action such as cell replacement, the release of trophic
factors and possible anti-inﬂammatory effects. In order to ensure
delivery of therapeutically relevant amounts of enzyme, it is possible
to engineer wild type neural stem cells (or indeed autologous neural
stem cells were they to be available) to overexpress the relevant
enzyme, thus combining stem cell transplantation with gene therapy
to maximize potential therapeutic beneﬁt.
To date these approaches have been evaluated in mouse models of
several LSDs. The ﬁrst demonstration of the therapeutic potential of
neural stemcells came from studies in theMPSVIImouse [41]. Amurine
neural stem cell line was engineered to overexpress β-glucuronidase
(deﬁcient in MPS VII) and the cells were injected into the lateral
ventricles. Life-long cross-correctionwith enzyme resulted [41]. Similar
ﬁndings were achieved using human neural progenitors in the MPS VII
mouse. Success in other LSDs has subsequently been reported including
in Niemann–Pick disease types A [42]and C [43]and in Sandhoff disease
[44]. In the Sandhoff disease study clinical improvement in the mice
resulted from neonatal transplants using eithermouse or human neural
stemcells. From this study itwas suggested that the clinical beneﬁtmost
likely resulted from multiple mechanisms [44] (i.e. this is in essence
combination therapy). Very recently, a follow-up study in which the
transplant was given to Sandhoff mice during the symptomatic phase of
disease (to model better the likely clinical scenario) found that survival
and neural functionwere both improved (Jeyakumar et al., unpublished
observation).
Phase I clinical studies are being initiated by the company Stem
Cells Inc. in the USA in Batten disease (neuronal ceroid lipofuscinosis,
NCL) (ClinicalTrials.gov identiﬁer, NCT00337636). The outcome will
probably emerge in the next year or so and will be of considerable
interest to those interested in using neural stem cells for treating
human neurodegenerative diseases, including LSDs. However, there
will remain technical and ethical issues: which cells fromwhat source
can be expanded to a scale that will allow translation into the clinic
and will their use be acceptable to politicians, society or both [45]?
6. ERT
In principle, therapeutic cross-correction does not require the
functional enzyme to be synthesised endogenously. If sufﬁcient
amounts of high purity enzyme could be made in the laboratory,
then this could be administered to the patient by intravenous infusion.
Although exogenous enzyme administered in this way would not be
able to cross the blood brain barrier and access the CNS, it should be
possible to augment enzyme activity in other non-neural tissues [28].
Such enzyme replacement therapywas ﬁrst developed for Gaucher
disease. Brady and colleagues initially used an enzyme preparation
puriﬁed from human placenta [46]. The pivotal clinical trial involved
12 patients in an open label, uncontrolled study which showed
decrease in organomegaly and improvements in blood counts over a
6 month period [47]. Alglucerase was licensed on the basis of this
efﬁcacy data. Several years later, it was replaced by the recombinant
enzyme imiglucerase.
ERT for non-neuronopathic Gaucher disease has been a great
success [48]. It is highly effective in treating visceral disease and,
although there are occasional patients on ERT who suffer ongoing
skeletal complications, for the most part the bone disease responds
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experience has also been very satisfying for their doctors. It is easy to
monitor response by measuring organ size and blood counts and the
development of sensitive biochemical markers, such as chitotriosi-
dase, has allowed the dose of enzyme to be titrated against disease
activity [50], maintaining patients' QoL and leading to considerable
cost savings. Therapy has also been very safe. Some patients do
develop antibodies against the enzyme but the associated infusion
reactions are generally easy to manage and the efﬁcacy of treatment
seems to be maintained. Over time patients become tolerized and the
antibody titres fall.
This success led to attempts to use ERT in other LSDs [51]. Two
different α-galactosidase enzymes have been developed for use in
Fabry disease, one made by recombinant technology in CHO cells
(agalsidase-β) and the other by overexpression of the native gene in a
cultured human cell line (agalsidase-α).
Although Fabry disease is another glycosphingolipidosis, its
pathobiology is very different from that of Gaucher disease. Whilst
in type 1 Gaucher pathological storage is essentially conﬁned to
macrophages of the reticuloendothelial system, which are readily
accessible to enzyme infused intravenously, in Fabry multiple cell
types in multiple organs are affected [52]. Clinically, Fabry causes
vascular, cardiac and renal disease. Although storage in endothelial
cells, resulting in vessel narrowing and ischaemia, has an important
role to play, it is not responsible for all the pathology, and a successful
treatment will also have to augment other cell types in the kidney and
heart, and possibly elsewhere as well. Therefore, the pharmacody-
namics of ERT for Fabry are very different from those for Gaucher. The
situation is further complicated by the fact that female heterozygotes
for Fabry, which is an X-linked disorder, often develop signs and
symptoms and, rarely, can have disease which is as severe as male
hemizygotes [53]. To some extent this is thought to relate to skewed
X-inactivation, but it does suggest that cross-correction in Fabry may
not be efﬁcient for all cell types.
Therefore it is perhaps not surprising that the experience to date
with ERT for Fabry has not been as satisfying as that in Gaucher. The
efﬁcacy data used in the licensing applications of both enzymes relied
heavily on surrogate end-points [54,55]. In both cases there was a
marked decrease in plasma Gb3, the substrate of the α-galactosidase
enzyme. The studies using agalsidase-β also showed large decreases
in Gb3 concentration in liver (an organ which has no relevance in the
clinical presentation of Fabry), with smaller reductions in kidney and
heart biopsies. Recently, the central role of Gb3 in Fabry disease, and
its relevance as a surrogate marker, have been questioned. It appears
possible that the lyso derivative of Gb3 (globotriaosylsphingosine)
may be the pathologically relevant metabolite [56]. This ﬁnding
highlights the fact that in many of these disorders our lack of
understanding of their pathophysiology is hindering our ability to
develop truly effective therapies.
The studies using agalsidase-α did manage to show a statistically
signiﬁcant improvement in QoL as a primary end-point. The
agalsidase-β study relied on the surrogate end-point of clearance of
storage from vascular endothelial cells in multiple organs: clearance
from other cell types was less impressive. Both preparations were
granted a license in Europe but in the US only agalsidase-β was
licensed, on the basis that orphan drug legislation guarantees
marketing exclusivity.
Subsequently, there have been reports, using both preparations, of
improvements in various measures of function of all the organs
involved (reviewed in [52]). It has, however, been difﬁcult to obtain
direct demonstrations of clinically relevant improvements, particu-
larly in glomerular ﬁltration rate (GFR), which is the easiest clinical
parameter to monitor. A recent large placebo-controlled study of
agalsidase-β in patients with signiﬁcant renal impairment does show
that ERT can reduce the incidence of renal and vascular events, but
that this effect depends on baseline renal function [57]. There maytherefore be a point in the natural history of Fabry after which
initiation of ERT will have no signiﬁcant effect on disease progression,
although it is still possible that there will be beneﬁts in terms of
symptom control.
The difﬁculties in measuring efﬁcacy pose challenges for physi-
cians treating patients with Fabry. The situation would be much
improved if, as in Gaucher, there were reliable biomarkers which
could be used to monitor the response to therapy and inform
treatment decisions [50]. This might also help to resolve issues
surrounding dosing: although agalsidase-α is given at one ﬁfth of the
dose of agalsidase-β, both preparations are reported to be efﬁcacious
and there is no pharmacological evidence that agalsidase-α is any
more potent than agalsidase-β [58,59]. The high cost of treating a
patient is the same for both preparations.
Therefore, in Fabry disease the real hope is that the institution of
ERT early in the disease, perhaps even before symptoms start, will
prevent the development of the complications which are life limiting
in this disorder. Treating paediatric patients with ERT does result in
improvement in symptoms and reductions in Gb3 storage [60]. We
hope that in 20 years time we will have a cohort of young men who
have been treated since childhood and who will have responded to
therapy much better than the current cohort of older patients, who
have been treated relatively late on, once pathological changes have
been established.
A number of the issues arising with ERT for Fabry recur when we
consider enzyme treatment for the mucopolysaccharidoses. These
disorders also involve multiple cell types in multiple tissues [3]. In all
cases, as in Gaucher, hepatosplenomegaly responds rapidly to the
administration of intravenous enzyme [61–63]. There is also a marked
reduction in the amount of GAG excreted in the urine. The functional
problems these patients have, however, are due to skeletal dysostosis
and involvement of the soft tissues, heart and lungs. Improvements in
measures such as joint mobility, timed walks and vital capacity,
though often statistically signiﬁcant, have not been nearly as dramatic
as those in the surrogate markers and it is not yet clear whether there
is any scope for improvement of the skeletal features [64]. Currently,
due to the inability of enzyme to cross the blood brain barrier, ERT is
not recommended for patients with CNS involvement.
The most recent condition to beneﬁt from ERT is glycogen storage
disease type II (GSD II, acid maltase deﬁciency, Pompe disease) [65].
This is primarily a disease of muscle, whichmakes the targeting of ERT
more straightforward. Again, there is a spectrum of disease activity
with the most severe, infantile-onset cases presenting in the ﬁrst few
weeks of life with a combined skeletal and cardiomyopathy which,
historically, was universally rapidly fatal [66]. Later onset cases
present as a progressive proximal myopathy, which can also involve
the diaphragms, giving rise to respiratory failure, but in which the
cardiac muscle is spared [67]. ERT was initially developed for the
infantile form, and it has proved to be lifesaving, reversing the
cardiomyopathy [68]. The skeletal myopathy has proven to be much
harder to reverse and, once established on invasive ventilation infants
rarely become independent of it. If treatment is started early enough,
however, it is possible to prevent the development of signiﬁcant
skeletal myopathy and the motor development of these children
appears to be good [69].
Experience of ERT in late-onset GSD II consists of case reports and
small series rather than clinical trials (although a large placebo-
controlled study is underway) [69]. This evidence is, however,
encouraging, and it appears that treatment can stop disease progres-
sion and that, in at least some cases, there is the potential for real
improvements in muscle strength with better respiratory function
and improved mobility. On the basis of these ﬁndings, ERT has been
licensed for use in GSD II patients of all ages.
Therefore, early experience with ERT for GSD II is more like that
with Gaucher disease than with the other, more pathobiologically
diverse conditions for which enzyme treatment has been developed.
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in glycogen storage in skeletal muscle is about ten times more than
that used in treating the other LSDs.
7. Gene therapy
Gene therapy has been evaluated in animal models of several
lysosomal storage diseases [70]. The broad consensus is that gene
therapy using a range of viral vectors (the current favourites being
based on adeno-associated and lentiviruses) results in global gene
expression and effective enzyme cross-correction in a wide variety of
mouse models [71]. The major problem that now needs to be
overcome is to transfer these ﬁndings to larger brains (the human
brain has a volume over 2000 times greater than the mouse brain).
The larger animal models of LSDs, such as the dog models of MPS
disorders, have been particularly important in the scale-up which will
be required before undertaking clinical studies. Safety issues remain a
concern regarding themethod of delivery (intracranial injections), the
biosafety and immunogenicity of the vectors themselves and the
potential need for immunosuppressive regimes in diseases where the
individual is enzyme null and therefore has no immunological
tolerance to the corrective enzyme.
The clinical data on gene therapy trials in LSDs is very limited to
date. Early attempts to treat Gaucher disease using autologous bone
marrow progenitor cells transduced with a retrovirus carrying the
glucocerebrosidase gene [72] were ultimately unsuccessful due to a
failure of engraftment, probably because the transduced cells had no
long-term survival advantage. More recently there have been phase I
trials of gene delivery to the brain in neurodegenerative LSDs. One of
these studies, in Batten disease, has recently been reported [73], and it
is possible that gene therapy will be a real therapeutic possibility for
these diseases in the future.
8. Enzyme stabilisation
In some cases, LSDs are due tomutations which cause instability of
the enzyme [2]. One approach to therapy in these cases is to use small
molecules that enhance folding or facilitate stabilisation of the active
site of the enzyme, so called chaperone therapy [74]. The majority of
studies to date have used carbohydrate mimetics that are actually
inhibitors of the relevant lysosomal hydrolases. The use of these
inhibitors at low “sub-inhibitory” concentrations stabilises the
conformation of the enzyme, allowing it to avoid degradation by the
quality control mechanisms of the cell and to reach the lysosome
intact. Here, once the “chaperone” molecule has dissociated from the
enzyme, it can express its residual activity and storage can be
reversed/reduced [74]. Clinical proof of principle for this approach has
been obtained using infusion of galactose in a patient with Fabry
disease [75]. A synthetic sugar is currently in clinical trials in Fabry
disease with trials initiated or planned in Gaucher and Pompe disease
[74] (Amicus Therapeutics). The main challenge is to get the dosing
right so that enzyme activity is enhanced, not inhibited, and this may
require some unorthodox dosing regimens with periods of therapy
followed by periods of drug withdrawal. Time will tell whether this
can be achieved in practice in a clinical setting.
Very recently another approach has been suggested that utilizes
calcium modulation of the ER in order to promote folding of
misfolded proteins [76]. Speciﬁcally two small molecule calcium
channel blockers (diltiazem and verapamil) used for treating
hypertension have been shown to restore enzyme function in
ﬁbroblasts from patients with Gaucher disease, alpha-mannosidosis
and MPS IIIa. The approximately 2-fold increase in residual enzyme
activity may or may not be enough to achieve clinical improvement
and so animal studies will be required to provide in vivo proof of
principle and long-term safety issues arising from using this non-
speciﬁc approach will require careful evaluation in patients withLSDs. Animals with instability mutations will of course be required
for these proof of principle studies, currently none are available.
9. Substrate reduction therapy
Another small molecule therapy is termed substrate reduction
therapy (SRT) [77]. This is the ﬁrst and only small molecule approach
to LSD treatment to reach routine clinical practice to date and was
developed over a 10 year period from basic discovery to regulatory
approval. The therapy uses a drug that partially inhibits glyco-
sphingolipid (GSL) biosynthesis, targeting glucosylceramide synthase
the enzyme that catalyses the ﬁrst committed step in GSL biosynthesis
[78]. As a result, fewer GSL molecules are synthesised so fewer GSLs
enter the lysosome for catabolism. Any residual enzyme activity
present can therefore better cope with degrading these molecules, as
the rate of biosynthesis better matches the rate of catabolism. There
are twomajor advantages of this approach. Firstly, a single drug can be
used to treat diseases that involve the storage of any glucosylcer-
amide-derived GSL (for example, Gaucher, Fabry, the GM1 and GM2
gangliosidoses and diseases such as Niemann–Pick type C (NPC) in
which GSLs are stored secondarily to the primary defect [5]). The
second advantage is that some small molecules can cross the blood
brain barrier and so could potentially beneﬁt diseases with storage in
the brain (the majority of these disorders) [20].
SRT uses an imino sugar drug, N-butyldeoxynojirimycin (NB-DNJ,
miglustat). Proof of principle of this approach was demonstrated in
an in vitro model of Gaucher disease [78]. Subsequent studies in
mouse models of Tay–Sachs [79], Sandhoff [80], Fabry [81], GM1
gangliosidosis [82] and NPC [83] have demonstrated the general
utility of this drug in GSL storage disorders. The mouse models with
CNS pathology (Sandhoff, GM1 and NPC) showed delayed symptom
onset, better maintenance of function and extended survival
illustrating that enough drug crossed the blood brain barrier to be
of therapeutic value [20].
Commercial considerations dictated that the initial clinical devel-
opment of miglustat was for type 1 Gaucher, a relatively common
condition inwhich a market for therapy had already been established.
A clinical trial in enzyme naive patients showed that SRT was effective
in reducing organomegaly, and improving blood counts and biochem-
ical markers of disease activity [84,85]. The response seen in this
relatively mildly affected cohort was broadly similar to what would
have been expected with ERT, although it may have taken a little
longer to develop [86].
Miglustat is a small molecule and, as would be expected, its
biological effects are not as ‘clean’ as those of imiglucerase; SRT has
more side effects than ERT. Minor gastrointestinal symptoms, and
particularly diarrhoea, are common after initiation of therapy, but are
usually transitory. These probably relate to the inhibition of intestinal
disaccharidases by miglustat. Tremor is also common and concern
about possible peripheral neuropathy in a small number of patients
remains. It is now proposed that peripheral neuropathy can be a
feature of the disease itself [87], although it had never been
recognised before the introduction of miglustat.
Miglustat is licensed for use in patients with mild to moderate
disease who are unwilling or unable to take ERT [88]. The decision to
use miglustat involves balancing the beneﬁt of the convenience of oral
therapy against the side effect proﬁle. There is an ongoing clinical
development program (ClinicalTrials.gov identiﬁer NCT00319046).
As well as being a potential competitor to ERT in the treatment of
Gaucher, and indeed Fabry, miglustat has the potential to be the ﬁrst
speciﬁc therapy for the neurological glycosphingolipid storage
disorders. Small clinical trials have been performed in type 3 Gaucher,
late-onset Tay–Sachs and NPC [89,90].
Performing clinical trials in such rare, progressive neurodegenera-
tive diseases has proven challenging. Whilst the therapeutic goal
would be for early treatment to stop the eventual development of
742 F.M. Platt, R.H. Lachmann / Biochimica et Biophysica Acta 1793 (2009) 737–745neurodegeneration, and for treatment of patients with established
disease to slow or halt their inevitable decline, regulatory agencies
demand deﬁned end-points and commercial considerations dictate
that clinical trials are of limited duration. Deﬁning hard clinical end-
points in these conditions is not easy. For the trials in type 3 Gaucher
and NPC, measurements of visual saccades were chosen.
In the Gaucher trial, there was no signiﬁcant improvement in
vertical saccadic eye movement velocity, or any other neurological
outcomemeasure, over a two year treatment period [89]. To expect an
improvement in established neurological signs is optimistic and it is
not clear whether the investigators felt that the patients' overall
condition had stabilised.
In NPC the results of SRT have been more encouraging [90]. After
one year of treatment, horizontal saccadic eye movement velocity had
actually improved slightly. There were also improvements in
functional measures of swallowing. These ﬁndings are remarkable
and it is to be hoped that SRT for this condition is developed further.
10. Combination therapy
Due to the complexity of the pathogenic cascade in LSDs there are
multiple potential clinical intervention points that each target unique
aspects of pathology. It seems logical that if therapies are combined
that target different aspects of the disease the outcome may be better
than either therapy alone. This concept has been tested in a mouse
model of Sandhoff disease and synergy reported combining SRT with
BMT [91], neural stem cell therapy [44] and NSAIDs [25]. To date,
combination therapy has not been evaluated clinically.
11. The problem of central nervous system disease
Despite the great progress which has been made in treating LSDs
over the past 20 years, we still lack satisfactory therapies for brain
disease. Bone marrow transplantation, if performed early enough, may
be able to prevent progression of nervous systemdisease, but procedure
related morbidity and mortality are high and BMTcannot be performed
at all in older patients. There are animal studies showing efﬁcacy of ERT.
In a mouse model of metachromatic leucodystrophy, although periph-
eral infusion of arylsulfatase-A does not lead to any increase in enzyme
activity within the brain, there is a reduction in storage material and
evidence for clinical improvement [92]. The mechanism for this
clearance of substrate is not clear, but clinical development of ERT is
currently underway. In a dogmodel ofMPS I recombinant enzyme given
intra-thecally at high dose has led to increases in enzyme activity and
reduction in GAG storage within the brain [93]. However, there is no
evidence that currently licensedenzyme therapies have anyeffecton the
CNS manifestations of LSDs. Although small molecule therapies such as
SRT and enzyme enhancement therapy (so called chaperone therapy,
see above) could affect storage in the brain, these approaches are both
mutation speciﬁc, requiring residual enzyme activity, and will not be
suitable for all patients.
Even if new therapies such as stem cells prove effective, it is
unlikely that they will be able to completely reverse pathology in the
brain. Where disability is due to inﬂammation or to cellular
dysfunction secondary to lysosomal storage, there is the potential to
restore normal function, but neuronal loss and scarring are probably
irreversible processes. There is also the possibility, particularly with
approaches such as SRT, that treatment will slow disease progression
rather than stopping it. In this case, we run the risk of prolonging the
terminal stages of disease without improving quality of life.
A similar ethical concern applies to some presently available ERTs.
Although we can treat systemic manifestations of disease, for diseases
where the brain is affected, we cannot stop neurological progression.
Thus ERT is not recommended for the forms of MPS I where there is
cognitive involvement. There is also the possibility that by successfully
treating the peripheral manifestations of disease and prolonging life,ERT may unmask latent CNS involvement in diseases, which are
currently thought not to affect the brain. We know that Gaucher
disease can be associated with a variety of neurological manifestations
[94] and it is possible that, as they grow older, patients with type 1
Gaucher disease successfully treated with ERT may develop Parkinso-
nian syndromes or other neuronopathic features traditionally asso-
ciated with type 3 disease.
12. When to treat: should we be screening for LSDs?
Left untreated, LSDs are progressive conditions. Where effective
treatments are available there is no doubt that they should be
introduced early on in the course of disease. It is in the nature of LSDs,
however, that the disease course is variable and unpredictable; many
patients with attenuated forms of disease will not develop signs or
symptoms of disease until they are well into adulthood. If we are to
ensure that our patients beneﬁt from the maximum efﬁcacy of
treatment, should we be screening populations so that we can initiate
therapy in the presymptomatic phase? These are invasive and
expensive treatments and the question of early treatment raises
ethical and health economic issues; the answer will depend on which
therapy for which disease is being considered.
When high risk populations are screened for Gaucher disease it has
been shown that certain common mutant genotypes have a very low
penetrance [95]. Most patients who develop clinically signiﬁcant
disease present with symptoms or signs, which relate to organome-
galy and pancytopenia. If ERT is initiated at the time of presentation,
these are reversible. The number of patients who present with bony
involvement is small. Knowledge of genotype does not help in
predictingwho theywill be. In type 1 Gaucher, efforts should be aimed
at educating clinicians about the disease and its treatment so that
when patients do present clinically, diagnosis is not delayed.
In Fabry disease, many young men present with cardiomyopathy,
renal failure or stroke. Effective management of Fabry would involve
identifying these individuals before they have sustained irreversible
damage to the heart, kidneys and/or brain, and instituting a therapy,
which would prevent disease progression. In fact, a full clinical history
will reveal that most of these patients suffered from symptoms in
childhood, such as acroparaesthesiae and lack of sweating, which if
investigated at the time would have led to a much earlier diagnosis,
perhaps opening a window for timely institution of ERT. Although
genetic screening of families can be very useful, the role of screening
populations for Fabry is not clear. Population screening in Italy
suggests that up to 1 in 3000 people have potentially pathogenic
mutations in their alpha-galactosidase gene [96]. This is an order of
magnitude higher than the recognised prevalence of Fabry disease and
one could not consider treating so many normal children. If current
clinical experience does suggest that early intervention can prevent
end-organ damage, then perhaps screening for null mutations will be
the way forward, as it seems likely that these would inevitably lead to
disease if present in the hemizygous state.
In infantile Pompe disease it is quite clear that ERT must be started
as early as possible if the outcome is to be good. The challenge for
screening will be to differentiate those babies destined to develop
severe disease with cardiomopathy, from those who will have late-
onset disease and in whom careful clinical follow-up could be used to
determine the point at which treatment should be started.
In MPS I and II it is not clear to what extent early institution of
therapy will prevent skeletal dysostosis. If screening is undertaken,
then it will be necessary to differentiate those children who will
develop CNS involvement, for whom ERT is not an appropriate
treatment.
If effective treatment becomes available for the neurodegenerative
LSDs, then it will be crucial that it is initiated as early as possible as any
damage to the brain will be irreversible. In this situation, the case for
screening will be urgent and compelling.
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to make if we could reliably predict the onset and severity of disease
from the results of screening tests. Although there are some well
characterised ‘severe’ genotypes, in the majority of cases it is not
possible to make reliable predictions. A better understanding of the
pathobiology of these diseases might lead to the development of
biomarkers which would allow us to accurately prognosticate and to
introduce therapy at the most appropriate point in the disease
course.
13. The future
In summary, despite the rarity and complexity of LSDs there has
been remarkable progress over the past two decades, with several
innovative therapies now approved for clinical use or in clinical trials.
There is however, still a long way to go and there is considerable
research and clinical activity being focused on improving efﬁcacy but
also, and crucially, on gaining a better understanding of the
pathophysiology of these disorders. There is little doubt that this
latter endeavour will identify novel approaches to therapy that may
alone or in combination with other treatments improve quality of life
for patients in the future.
References
[1] P.J. Meikle, J.J. Hopwood, A.E. Clague, W.F. Carey, Prevalence of lysosomal storage
disorders, Jama 281 (1999) 249–254.
[2] B. Winchester, Primary defects in lysosomal enzymes, In: F.M. Platt, S.U. Walkley
(Eds.), Lysosomal Disorders of the Brain, Oxford University Press, Oxford, 2004,
pp. 81–130.
[3] J.E. Wraith, Clinical aspects and diagnosis, In: F.M. Platt, S.U. Walkley (Eds.),
Lysosomal Disorders of the Brain, Oxford University Press, Oxford, 2004, pp.
50–77.
[4] F.M. Platt, S.U. Walkley, Lysosomal defects and storage, In: F.M. Platt, S.U. Walkley
(Eds.), Lysosomal Disorders of the Brain, Oxford University Press, Oxford, 2004,
pp. 32–49.
[5] S.U. Walkley, Secondary accumulation of gangliosides in lysosomal storage
disorders, Semin. Cell Dev. Biol. 15 (2004) 433–444.
[6] J.E. Wraith, Lysosomal disorders, Semin. Neonatol. 7 (2002) 75–83.
[7] B. Winchester, A. Vellodi, E. Young, The molecular basis of lysosomal storage
diseases and their treatment, Biochem. Soc. Trans. 28 (2000) 150–154.
[8] E. Beutler, G.A. Grabowski, Gaucher Disease, In: C.R. Scriver, A.L. Baudet, W.S. Sly,
D. Valle (Eds.), The Metabolic and Molecular Bases of Metabolic Disease, 8th ed.,
McGraw-Hill, New York, 2001, pp. 3635–3668.
[9] K. Wong, E. Sidransky, A. Verma, T. Mixon, G.D. Sandberg, L.K. Wakeﬁeld, A.
Morrison, A. Lwin, C. Colegial, J.M. Allman, R. Schiffmann, Neuropathology
provides clues to the pathophysiology of Gaucher disease, Mol. Genet. Metab. 82
(2004) 192–207.
[10] T.M. Cox, Gaucher disease: understanding the molecular pathogenesis of
sphingolipidoses, J. Inherit. Metab. Dis. 24 (Suppl. 2) (2001) 106–121 discussion
187–108.
[11] R.H. Lachmann, I.R. Grant, D. Halsall, T.M. Cox, Twin pairs showing discordance of
phenotype in adult Gaucher's disease, Q JM 97 (2004) 199–204.
[12] K. Simons, J. Gruenberg, Jamming the endosomal system: lipid rafts and lysosomal
storage diseases, Trends Cell Biol. 10 (2000) 459–462.
[13] A.H. Futerman, G. van Meer, The cell biology of lysosomal storage disorders, Nat.
Rev., Mol. Cell Biol. 5 (2004) 554–565.
[14] M. Fuller, T. Rozaklis, M. Lovejoy, K. Zarrinkalam, J.J. Hopwood, P.J. Meikle,
Glucosylceramide accumulation is not conﬁned to the lysosome in ﬁbroblasts
from patients with Gaucher disease, Molec. Genet. Metab. 93 (2008) 437–443.
[15] D. Pelled, E. Lloyd-Evans, C. Riebeling, M. Jeyakumar, F.M. Platt, A.H. Futerman,
Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase
in a mouse model of Sandhoff disease and prevention by treatment with N-
butyldeoxynojirimycin, J. Biol. Chem. 278 (2003) 29496–29501.
[16] C.S. Chen, M.C. Patterson, C.L. Wheatley, J.F. O'Brien, R.E. Pagano, Broad screening
test for sphingolipid-storage diseases, Lancet 354 (1999) 901–905.
[17] R.E. Pagano, V. Puri, M. Dominguez, D.L. Marks, Membrane trafﬁc in sphingolipid
storage diseases, Trafﬁc 1 (2000) 807–815.
[18] R.H. Lachmann, D. te Vruchte, E. Lloyd-Evans, G. Reinkensmeier, D.J. Sillence, L.
Fernandez-Guillen, R.A. Dwek, T.D. Butters, T.M. Cox, F.M. Platt, Treatment with
miglustat reverses the lipid-trafﬁcking defect in Niemann–Pick disease type C,
Neurobiol. Dis. 16 (2004) 654–658.
[19] J.J. Hopwood, A.C. Crawley, R.M. Taylor, Spontaneous and engineered mammalian
storage disease models, In: F.M. Platt, S.U. Walkley (Eds.), Lysosomal Disorders of
the Brain, vol. 1, Oxford Univ. Press, Oxford, 2004, pp. 257–289.
[20] M. Jeyakumar, R.A. Dwek, T.D. Butters, F.M. Platt, Storage solutions: treating
lysosomal disorders of the brain, Nat. Rev. Neurosci. 6 (2005) 713–725.
[21] M. Jeyakumar, R. Thomas, E. Elliot-Smith, D.A. Smith, A.C. van der Spoel, A. d'Azzo,
V.H. Perry, T.D. Butters, R.A. Dwek, F.M. Platt, Central nervous system inﬂamma-tion is a hallmark of pathogenesis in mouse models of GM1 and GM2
gangliosidosis, Brain 126 (2003) 974–987.
[22] R. Wada, C.J. Tifft, R.L. Proia, Microglial activation precedes acute neurodegenera-
tion in Sandhoff disease and is suppressed by bone marrow transplantation, Proc.
Natl. Acad. Sci. U. S. A. 97 (2000) 10954–10959.
[23] A. Yamaguchi, K. Katsuyama, K. Nagahama, T. Takai, I. Aoki, S. Yamanaka, Possible
role of autoantibodies in the pathophysiology of GM2 gangliosidoses, J. Clin.
Invest. 113 (2004) 200–208.
[24] Y.P. Wu, R.L. Proia, Deletion of macrophage-inﬂammatory protein 1 alpha retards
neurodegeneration in Sandhoff disease mice, Proc. Natl. Acad. Sci. U. S. A. 101
(2004) 8425–8430.
[25] M. Jeyakumar, D.A. Smith, I.M. Williams, M.C. Borja, D.C. Neville, T.D. Butters, R.A.
Dwek, F.M. Platt, NSAIDs increase survival in the Sandhoff disease mouse: synergy
with N-butyldeoxynojirimycin, Ann. Neurol. 56 (2004) 642–649.
[26] A. Hasilik, P. Lemansky, Defects in lysosomal enzyme trafﬁcking, In: F.M. Platt, S.U.
Walkley (Eds.), Lysosomal Disorders of the Brain, Oxford Univ. Press, Oxford, 2004,
pp. 141–169.
[27] D. Reczek, M. Schwake, J. Schroder, H. Hughes, J. Blanz, X. Jin, W. Brondyk, S.
Van Patten, T. Edmunds, P. Saftig, LIMP-2 is a receptor for lysosomal mannose-
6-phosphate-independent targeting of beta-glucocerebrosidase, Cell 131 (2007)
770–783.
[28] E.F. Neufeld, Enzyme replacement therapy, In: F.M. Platt, S.U. Walkley (Eds.),
LysosomalDisorders of theBrain,OxfordUniversity Press,Oxford, 2004,pp. 327–338.
[29] W. Krivit, C. Peters, E.G. Shapiro, Bone marrow transplantation as effective
treatment of central nervous system disease in globoid cell leukodystrophy,
metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosido-
sis, aspartylglucosaminuria, Hurler, Maroteaux–Lamy, and Sly syndromes, and
Gaucher disease type III, Curr. Opin. Neurol. 12 (1999) 167–176.
[30] P.M. Hoogerbrugge, O.F. Brouwer, P. Bordigoni, O. Ringden, P. Kapaun, J.J. Ortega, A.
O'Meara, G. Cornu, G. Souillet, D. Frappaz, et al., Allogeneic bone marrow
transplantation for lysosomal storage diseases. The European Group for Bone
Marrow Transplantation, Lancet 345 (1995) 1398–1402 issn: 0140–6736.
[31] G. Souillet, N. Guffon, I. Maire, M. Pujol, P. Taylor, F. Sevin, N. Bleyzac, C. Mulier, A.
Durin, K. Kebaili, C. Galambrun, Y. Bertrand, R. Froissart, C. Dorche, L. Gebuhrer, C.
Garin, J. Berard, P. Guibaud, Outcome of 27 patients with Hurler's syndrome
transplanted from either related or unrelated haematopoietic stem cell sources,
Bone Marrow Transplant. 31 (2003) 1105–1117.
[32] L.E. Polgreen, J. Tolar, M. Plog, J.H. Himes, P.J. Orchard, C.B. Whitley, B.S. Miller, A.
Petryk, Growth and endocrine function in patients with Hurler syndrome after
hematopoietic stem cell transplantation, Bone Marrow Transplant. 41 (2008)
1005–1011.
[33] T. Lucke, A.M. Das, H. Hartmann, K.W. Sykora, F. Donnerstag, G. Schmid-Ott, L.
Grigull, Developmental outcome in ﬁve childrenwith Hurler syndrome after stem
cell transplantation: a pilot study, Dev. Med. Child Neurol. 49 (2007) 693–696.
[34] M.L. Escolar, M.D. Poe, J.M. Provenzale, K.C. Richards, J. Allison, S. Wood, D.A.
Wenger, D. Pietryga, D. Wall, M. Champagne, R. Morse, W. Krivit, J. Kurtzberg,
Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease,
N. Engl. J. Med. 352 (2005) 2069–2081.
[35] Z.Y. Lim, A.Y.L. Ho, S. Abrahams, A. Fensom, M. Aldouri, A. Pagliuca, C. Shaw, G.J.
Mufti, Sustained neurological improvement following reduced-intensity con-
ditioning allogeneic haematopoietic stem cell transplantation for late-onset
Krabbe disease, Bone Marrow Transplant. 41 (2008) 831–832.
[36] J.J. Boelens, Trends in haematopoietic cell transplantation for inborn errors of
metabolism, J. Inherit. Metab. Dis. 29 (2006) 413–420.
[37] A. Vellodi, E. Young, A. Cooper, V. Lidchi, B. Winchester, J.E. Wraith, Long-term
follow-up following bone marrow transplantation for Hunter disease, J. Inherit.
Metab. Dis. 22 (1999) 638–648.
[38] M. Gorg, W. Wilck, B. Granitzny, A. Suerken, Z. Lukacs, D. Xiaoqi, M. Schulte-
Markwort, A. Kohlschutter, Stabilization of juvenile metachromatic leukodystro-
phy after bone marrow transplantation: a 13-year follow-up, J. Child. Neurol. 22
(2007) 1139–1142.
[39] D.W. Kennedy, J.L. Abkowitz, Kinetics of central nervous system microglial and
macrophage engraftment: analysis using a transgenic bone marrow transplanta-
tion model, Blood 90 (1997) 986–993.
[40] E.Y. Snyder, G.Q. Daley, M. Goodell, Taking stock and planning for the next decade:
realistic prospects for stem cell therapies for the nervous system, J. Neurosci. Res.
76 (2004) 157–168.
[41] E.Y. Snyder, R.M. Taylor, J.H. Wolfe, Neural progenitor cell engraftment corrects
lysosomal storage throughout the MPS VII mouse brain, Nature 374 (1995)
367–370.
[42] R.L. Sidman, J. Li, G.R. Stewart, J. Clarke, W. Yang, E.Y. Snyder, L.S. Shihabuddin,
Injection of mouse and human neural stem cells into neonatal Niemann–Pick A
model mice, Brain Res. 1140 (2007) 195–204.
[43] I. Ahmad, R.E. Hunter, J.D. Flax, E.Y. Snyder, R.P. Erickson, Neural stem cell
implantation extends life in Niemann–Pick C1 mice, J. Appl. Genet. 48 (2007)
269–272.
[44] J.P. Lee, M. Jeyakumar, R. Gonzalez, H. Takahashi, P.J. Lee, R.C. Baek, D. Clark, H.
Rose, G. Fu, J. Clarke, S. McKercher, J. Meerloo, F.J. Muller, K.I. Park, T.D. Butters, R.A.
Dwek, P. Schwartz, G. Tong, D. Wenger, S.A. Lipton, T.N. Seyfried, F.M. Platt, E.Y.
Snyder, Stem cells act through multiple mechanisms to beneﬁt mice with
neurodegenerative metabolic disease, Nat. Med. 13 (2007) 439–447.
[45] S.H. Cedar, J.A. Cooke, Z. Luo, M.J. Patel, S.L. Minger, From embryos to embryonic
stem cells: biopolitics and therapeutic potential, Reprod. Biomed. Online 13
(2006) 725–731.
[46] R.O. Brady, Enzyme replacement for lysosomal diseases, Annu. Rev. Med. 57
(2006) 283–296.
744 F.M. Platt, R.H. Lachmann / Biochimica et Biophysica Acta 1793 (2009) 737–745[47] N.W. Barton, R.O. Brady, J.M. Dambrosia, A.M. Di Bisceglie, S.H. Doppelt, S.C. Hill,
H.J. Mankin, G.J. Murray, R.I. Parker, C.E. Argoff, et al., Replacement therapy for
inherited enzyme deﬁciency-macrophage-targeted glucocerebrosidase for Gau-
cher's disease, N. Engl. J. Med. 324 (1991) 1464–1470.
[48] N.J. Weinreb, J. Charrow, H.C. Andersson, P. Kaplan, E.H. Kolodny, P. Mistry, G.
Pastores, B.E. Rosenbloom, C.R. Scott, R.S. Wappner, A. Zimran, Effectiveness of
enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2
to 5 years of treatment: a report from the Gaucher Registry, Am. J. Med.113 (2002)
112–119.
[49] K.B. Sims, G.M. Pastores, N.J. Weinreb, J. Barranger, B.E. Rosenbloom, S. Packman,
P. Kaplan, H. Mankin, R. Xavier, J. Angell, M.A. Fitzpatrick, D. Rosenthal,
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients
with skeletal manifestations of type 1 Gaucher disease: results of a 48-month
longitudinal cohort study, Clin. Genet. 73 (2008) 430–440.
[50] J.M. Aerts, C.E. Hollak, M. van Breemen, M. Maas, J.E. Groener, R.G. Boot,
Identiﬁcation and use of biomarkers in Gaucher disease and other lysosomal
storage diseases, Acta Paediatr. (Suppl. 94) (2005) 43–46 discussion 37–48.
[51] M. Rohrbach, J.T. Clarke, Treatment of lysosomal storage disorders: progress with
enzyme replacement therapy, Drugs 67 (2007) 2697–2716.
[52] J.T. Clarke, Narrative review: Fabry disease, Ann. Intern. Med.146 (2007) 425–433.
[53] K.D. MacDermot, A. Holmes, A.H. Miners, Anderson–Fabry disease: clinical
manifestations and impact of disease in a cohort of 60 obligate carrier females,
J. Med. Genet. 38 (2001) 769–775.
[54] C.M. Eng, M. Banikazemi, R.E. Gordon, M. Goldman, R. Phelps, L. Kim, A. Gass,
J. Winston, S. Dikman, J.T. Fallon, S. Brodie, C.B. Stacy, D. Mehta, R. Parsons, K.
Norton, M. O'Callaghan, R.J. Desnick, A phase 1/2 clinical trial of enzyme
replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety
studies, Am. J. Hum. Genet. 68 (2001) 711–722.
[55] R. Schiffmann, J.B. Kopp, H.A. Austin III, S. Sabnis, D.F. Moore, T. Weibel, J.E. Balow,
R.O. Brady, Enzyme replacement therapy in Fabry disease: a randomized
controlled trial, JAMA 285 (2001) 2743–2749.
[56] J.M. Aerts, J.E. Groener, S. Kuiper, W.E. Donker-Koopman, A. Strijland, R.
Ottenhoff, C. van Roomen, M. Mirzaian, F.A. Wijburg, G.E. Linthorst, A.C. Vedder,
S.M. Rombach, J. Cox-Brinkman, P. Somerharju, R.G. Boot, C.E. Hollak, R.O. Brady,
B.J. Poorthuis, Elevated globotriaosylsphingosine is a hallmark of Fabry disease,
Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2812–2817.
[57] M. Banikazemi, J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, M. McDonald, R.
Finkel, S. Packman, D.G. Bichet, D.G. Warnock, R.J. Desnick, Agalsidase-beta
therapy for advanced Fabry disease: a randomized trial, Ann. Intern. Med. 146
(2007) 77–86.
[58] K. Lee, X. Jin, K. Zhang, L. Copertino, L. Andrews, J. Baker-Malcolm, L. Geagan, H.
Qiu, K. Seiger, D. Barngrover, J.M. McPherson, T. Edmunds, A biochemical and
pharmacological comparison of enzyme replacement therapies for the glycolipid
storage disorder Fabry disease, Glycobiology 13 (2003) 305–313.
[59] H. Sakuraba, M. Murata-Ohsawa, I. Kawashima, Y. Tajima, M. Kotani, T. Ohshima, Y.
Chiba, M. Takashiba, Y. Jigami, T. Fukushige, T. Kanzaki, K. Itoh, Comparison of the
effects of agalsidase alfa and agalsidase beta on cultured human Fabry ﬁbroblasts
and Fabry mice, J. Hum. Genet. 51 (2006) 180–188.
[60] J.E. Wraith, A. Tylki-Szymanska, N. Guffon, Y.H. Lien, M. Tsimaratos, A. Vellodi,
D.P. Germain, Safety and efﬁcacy of enzyme replacement therapy with
agalsidase beta: an international, open-label study in pediatric patients with
Fabry disease, J. Pediatr. 152 (2008) 563–570 570 e561.
[61] P. Harmatz, R. Giugliani, I. Schwartz, N. Guffon, E.L. Teles, M.C. Miranda, J.E. Wraith,
M. Beck, L. Arash, M. Scarpa, Z.F. Yu, J. Wittes, K.I. Berger, M.S. Newman, A.M. Lowe,
E. Kakkis, S.J. Swiedler, Enzyme replacement therapy for mucopolysaccharidosis
VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study
of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human
arylsulfatase B or rhASB) and follow-on, open-label extension study, J. Pediatr. 148
(2006) 533–539.
[62] J. Muenzer, M. Gucsavas-Calikoglu, S.E. McCandless, T.J. Schuetz, A. Kimura, A
phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis
II (Hunter syndrome), Mol. Genet. Metab. 90 (2007) 329–337.
[63] J.E. Wraith, L.A. Clarke, M. Beck, E.H. Kolodny, G.M. Pastores, J. Muenzer, D.M.
Rapoport, K.I. Berger, S.J. Swiedler, E.D. Kakkis, T. Braakman, E. Chadbourne, K.
Walton-Bowen, G.F. Cox, Enzyme replacement therapy for mucopolysaccharidosis I:
a randomized, double-blinded, placebo-controlled, multinational study of recombi-
nant human alpha-L-iduronidase (laronidase), J. Pediatr. 144 (2004) 581–588.
[64] M. Sifuentes, R. Doroshow, R. Hoft, G. Mason, I. Walot, M. Diament, S. Okazaki, K.
Huff, G.F. Cox, S.J. Swiedler, E.D. Kakkis, A follow-up study of MPS I patients treated
with laronidase enzyme replacement therapy for 6 years, Mol. Genet. Metab. 90
(2007) 171–180.
[65] H.G. Hers, a-Glucosidase deﬁciency in generalised glycogen storage disease
(Pompe's disease), Biochem. J. 86 (1963) 11–16.
[66] P.S. Kishnani, W.L. Hwu, H. Mandel, M. Nicolino, F. Yong, D. Corzo, A retrospective,
multinational, multicenter study on the natural history of infantile-onset Pompe
disease, J. Pediatr. 148 (2006) 671–676.
[67] M.L. Hagemans, L.P. Winkel, P.A. Van Doorn, W.J. Hop, M.C. Loonen, A.J. Reuser, A.T.
Van der Ploeg, Clinical manifestation and natural course of late-onset Pompe's
disease in 54 Dutch patients, Brain 128 (2005) 671–677.
[68] P.S. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, W.L. Hwu, N. Leslie, J.
Levine, C. Spencer, M. McDonald, J. Li, J. Dumontier, M. Halberthal, Y.H. Chien, R.
Hopkin, S. Vijayaraghavan, D. Gruskin, D. Bartholomew, A. van der Ploeg, J.P. Clancy,
R. Parini, G. Morin, M. Beck, G.S. De la Gastine, M. Jokic, B. Thurberg, S. Richards, D.
Bali, M. Davison, M.A. Worden, Y.T. Chen, J.E. Wraith, Recombinant human acid
[alpha]-glucosidase: major clinical beneﬁts in infantile-onset Pompe disease,
Neurology 68 (2007) 99–109.[69] N.A. van der Beek, M.L. Hagemans, A.T. van der Ploeg, A.J. Reuser, P.A. van Doorn,
Pompe disease (glycogen storage disease type II): clinical features and enzyme
replacement therapy, Acta Neurol. Belg. 106 (2006) 82–86.
[70] M.S. Sands, Gene therapy, In: F.M. Platt, S.U. Walkley (Eds.), Lysosomal Disorders
of the Brain, Oxford Univ. Press, Oxford, 2004, pp. 409–430.
[71] M. Cardone, Prospects for gene therapy in inherited neurodegenerative diseases,
Curr. Opin. Neurol. 20 (2007) 151–158.
[72] J.A. Barranger, E.O. Rice, J. Dunigan, C. Sansieri, N. Takiyama, M. Beeler, J. Lancia, S.
Lucot, S. Scheirer-Fochler, T. Mohney, W. Swaney, A. Bahnson, E. Ball, Gaucher's
disease: studies of gene transfer to haematopoietic cells, Bailliere's Clin. Haematol.
10 (1997) 765–778.
[73] S. Worgall, D. Sondhi, N.R. Hackett, B. Kosofsky, M.V. Kekatpure, N. Neyzi, J.P. Dyke,
D. Ballon, L. Heier, B.M. Greenwald, P. Christos, M. Mazumdar, M.M. Souweidane,
M.G. Kaplitt, R.G. Crystal, Treatment of late infantile neuronal ceroid lipofuscinosis
by CNS administration of a serotype 2 adeno-associated virus expressing CLN2
cDNA, Hum. Gene Ther. 5 (2008) 463–474.
[74] J.Q. Fan, A counterintuitive approach to treat enzyme deﬁciencies: use of enzyme
inhibitors for restoring mutant enzyme activity, Biol. Chem. 389 (2008) 1–11.
[75] A. Frustaci, C. Chimenti, R. Ricci, L. Natale, M.A. Russo, M. Pieroni, C.M. Eng, R.J.
Desnick, Improvement in cardiac function in the cardiac variant of Fabry's disease
with galactose-infusion therapy, N. Engl. J. Med. 345 (2001) 25–32.
[76] T.W. Mu, D.M. Fowler, J.W. Kelly, Partial restoration of mutant enzyme home-
ostasis in three distinct lysosomal storage disease cell lines by altering calcium
homeostasis, PLoS Biol. 6 (2008) e26.
[77] F.M. Platt, T.D. Butters, Inhibition of substrate synthesis: a pharmacological
approach for glycosphingolipid storage disease therapy, In: F.M. Platt, S.U. Walkley
(Eds.), Lysosomal Disorders of the Brain, Oxford Univ. Press, Oxford, 2004, pp.
381–408.
[78] F.M. Platt, G.R. Neises, R.A. Dwek, T.D. Butters, N-butyldeoxynojirimycin is a novel
inhibitor of glycolipid biosynthesis, J. Biol. Chem. 269 (1994) 8362–8365.
[79] F.M. Platt, G.R. Neises, G. Reinkensmeier, M.J. Townsend, V.H. Perry, R.L. Proia,
B. Winchester, R.A. Dwek, T.D. Butters, Prevention of lysosomal storage in Tay–
Sachs mice treated with N-butyldeoxynojirimycin, Science 276 (1997)
428–431.
[80] M. Jeyakumar, T.D. Butters, M. Cortina-Borja, V. Hunnam, R.L. Proia, V.H. Perry, R.A.
Dwek, F.M. Platt, Delayed symptom onset and increased life expectancy in
Sandhoff disease mice treated with N-butyldeoxynojirimycin, Proc. Natl. Acad. Sci.
U. S. A. 96 (1999) 6388–6393.
[81] T. Heare, N.J. Alp, D.A. Priestman, A.B. Kulkarni, P. Qasba, T.D. Butters, R.A. Dwek, K.
Clarke, K.M. Channon, F.M. Platt, Severe endothelial dysfunction in the aorta of a
mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin
treatment, J. Inherit. Metab. Dis. 30 (2007) 79–87.
[82] E. Elliot-Smith, A.O. Speak, E. Lloyd-Evans, D.A. Smith, A.C. van der Spoel, M.
Jeyakumar, T.D. Butters, R.A. Dwek, A. d'Azzo, F.M. Platt, Beneﬁcial effects of
substrate reduction therapy in a mouse model of GM1 gangliosidosis, Molec.
Genet. Metab. 94 (2008) 204–211.
[83] M. Zervas, K.L. Somers, M.A. Thrall, S.U. Walkley, Critical role for glycosphingo-
lipids in Niemann–Pick disease type C, Curr. Biol. 11 (2001) 1283–1287.
[84] T. Cox, R. Lachmann, C. Hollak, J. Aerts, S. van Weely, M. Hrebicek, F. Platt, T.
Butters, R. Dwek, C. Moyses, I. Gow, D. Elstein, A. Zimran, Novel oral treatment of
Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate
biosynthesis, Lancet 355 (2000) 1481–1485.
[85] D. Elstein, C. Hollak, J.M. Aerts, S. vanWeely, M. Maas, T.M. Cox, R.H. Lachmann, M.
Hrebicek, F.M. Platt, T.D. Butters, R.A. Dwek, A. Zimran, Sustained therapeutic
effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I
Gaucher disease, J. Inherit. Metab. Dis. 27 (2004) 757–766.
[86] R.H. Lachmann, F.M. Platt, Substrate reduction therapy for glycosphingolipid
storage disorders, Expert Opin. Investig. Drugs 10 (2001) 455–466.
[87] J.L. Capablo, A. Saenz de Cabezon, J. Fraile, P. Alfonso, M. Pocovi, P. Giraldo,
Neurological evaluation of patients with Gaucher disease diagnosed as type 1,
J. Neurol. Neurosurg. Psychiatry 79 (2008) 219–222.
[88] T.M. Cox, J.M. Aerts, G. Andria, M. Beck, N. Belmatoug, B. Bembi, R. Chertkoff, S.
Vom Dahl, D. Elstein, A. Erikson, M. Giralt, R. Heitner, C. Hollak, M. Hrebicek, S.
Lewis, A. Mehta, G.M. Pastores, A. Rolfs, M.C. Miranda, A. Zimran, The role of the
iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I
(non-neuronopathic) Gaucher disease: a position statement, J. Inherit. Metab. Dis.
26 (2003) 513–526.
[89] A. Vellodi, C. Harris, C. DeVile, E. Davies, E. Fitzgibbon, L. Abel, P. Campbell, N. van
Schalk, W. Benko, M. Timmons, R. Schiffmann, Miglustat in Gaucher disease type
3, Eur. J. Hum. Genet. 15 (Suppl. 1) (2007) 347.
[90] M.C. Patterson, D. Vecchio, H. Prady, L. Abel, J.E. Wraith, Miglustat for treatment of
Niemann–Pick C disease: a randomised controlled study, Lancet Neurol. 6 (2007)
765–772.
[91] M. Jeyakumar, F. Norﬂus, C.J. Tifft, M. Cortina-Borja, T.D. Butters, R.L. Proia, V.H.
Perry, R.A. Dwek, F.M. Platt, Enhanced survival in Sandhoff disease mice receiving
a combination of substrate deprivation therapy and bonemarrow transplantation,
Blood 97 (2001) 327–329.
[92] U. Matzner, E. Herbst, K.K. Hedayati, R. Lullmann-Rauch, C. Wessig, S. Schroder, C.
Eistrup, C. Moller, J. Fogh, V. Gieselmann, Enzyme replacement improves nervous
system pathology and function in a mouse model for metachromatic leukody-
strophy, Hum. Mol. Genet. 14 (2005) 1139–1152.
[93] P. Dickson, M. McEntee, C. Vogler, S. Le, B. Levy, M. Peinovich, S. Hanson, M.
Passage, E. Kakkis, Intrathecal enzyme replacement therapy: successful treatment
of brain disease via the cerebrospinal ﬂuid, Mol. Genet. Metab. 91 (2007) 61–68.
[94] M. Biegstraaten, I.N. van Schaik, J.M. Aerts, C.E. Hollak, ‘Non-neuronopathic’
Gaucher disease reconsidered. Prevalence of neurological manifestations in a
745F.M. Platt, R.H. Lachmann / Biochimica et Biophysica Acta 1793 (2009) 737–745Dutch cohort of type I Gaucher disease patients and a systematic review of the
literature, J. Inherit. Metab. Dis. 31 (3) (2008) 337–349.
[95] M. Horowitz, M. Pasmanik-Chor, Z. Borochowitz, T. Falik-Zaccai, K. Heldmann, R.
Carmi, R. Parvari, H. Beit-Or, B. Goldman, L. Peleg, E. Levy-Lahad, P. Renbaum, S.
Legum, R. Shomrat, H. Yeger, D. Benbenisti, R. Navon, V. Dror, M. Shohat, N. Magal,N. Navot, N. Eyal, Prevalence of glucocerebrosidase mutations in the Israeli
Ashkenazi Jewish population, Hum. Mutat. 12 (1998) 240–244.
[96] M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan, H. Sakuraba, A.
Ponzone, R.J. Desnick, High incidence of later-onset Fabry disease revealed by
newborn screening, Am. J. Hum. Genet. 79 (2006) 31–40.
